The survey for the report was conducted from December 13, 2024 to January 10, 2025 with a nationally representative samples of 1500 US adults and 150 eye care providers from The Vision Council’s Research Advisory Panel.

VEVYE Access for All aims to reduce barriers to dry eye disease therapy via a partnership with PhilRx.

The grant will allow the research team to determine the novel mechanisms that convert immature eye lens precursors cells into functional transparent cells.

The system aids in the orthokeratology lens design process by syncing directly with topographers to create precise lens designs for the treatment of myopia in the matter of seconds.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy individuals.

Catch up on the top stories in optometry during the week of March 10-March 14.

The capital raise was completed in partnership with global alternative asset management firm TPH.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported.

The Preservative Freedom Coalition’s recent Glaucoma Patient Experience survey also found a need to better communication between patients and eye care providers.

The study, published in JAMA Network Open, found that only 8.2% of patients who were referred and received a glaucoma evaluation were diagnosed with glaucoma.

Cationic emulsion drops are characterized by their ability to retain cyclosporine A on the ocular surface.

The collaboration allows Topcon to become the exclusive global distributor of Inspire, RadiusXR’s new wearable vision testing platform.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

A recent study assessed the effect of a modified TCLB procedure that added deframing and decompression maneuvers to the LOFC and its support structures to obtain better results for both the lower and upper lids.

Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

VisionSpring, Eye Care Foundation, and Deckers Brands will provide screenings to 4600 factory workers over 18 days and will take place at 2 factories.

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous risk and help inform cost-effective methods for disease detection.